<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464074</url>
  </required_header>
  <id_info>
    <org_study_id>001-06-NAT</org_study_id>
    <nct_id>NCT00464074</nct_id>
  </id_info>
  <brief_title>Evaluation of Natalizumab for thE Relief of MS Associated FatiGue</brief_title>
  <acronym>ENER-G</acronym>
  <official_title>Multi-center, Open-Label Study to Evaluate the Effects of Natalizumab Treatment on Fatigue and Cognition in Subjects With Relapsing Forms of MS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to study the effects of TYSABRI® treatment on fatigue and cognition in&#xD;
      patients with relapsing forms of MS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TYSABRI® treatment has already demonstrated significant improvement in the quality of life&#xD;
      (QoL) of patients with MS. In particular, TYSABRI® add-on treatment to interferon beta-1a has&#xD;
      demonstrated improvement in fatigue as measured by the Modified Fatigue Impact Scale (MFIS).&#xD;
      Both patients and neurologists report that patients have experienced significant improvements&#xD;
      in fatigue shortly after initiating TYSABRI® treatment. Fatigue is both a common and a&#xD;
      disabling symptom of MS. Further, there is evidence that fatigue contributes to cognitive&#xD;
      difficulties in patients with MS. This study aims to study the effects of TYSABRI® treatment&#xD;
      on fatigue and cognition in patients with relapsing forms of MS.&#xD;
&#xD;
      The primary objective of this study is to determine the effects of TYSABRI® treatment on&#xD;
      fatigue in subjects with relapsing forms of MS as measured by changes in patient-reported&#xD;
      Visual Analog Scale for Fatigue (VAS-F).&#xD;
&#xD;
      Primary endpoint is the change in the following:&#xD;
&#xD;
      1. Visual Analog Scale for Fatigue (VAS-F) at three months after initiating treatment with&#xD;
      TYSABRI®.&#xD;
&#xD;
      Secondary objectives are to measure changes in patient-reported Modified Fatigue Impact Scale&#xD;
      (MFIS) and Fatigue Severity Scale (FSS).&#xD;
&#xD;
      Secondary endpoints are changes in the following:&#xD;
&#xD;
        1. Modified Fatigue Impact Scale (MFIS)&#xD;
&#xD;
        2. Fatigue Severity Scale (FSS)&#xD;
&#xD;
      The tertiary objective of this study is to explore for any effects of TYSABRI® treatment on&#xD;
      cognition by assessing changes in the Automated Neuropsychology Assessment Metrics (ANAM).&#xD;
&#xD;
      Tertiary endpoints are changes in the Automated Neuropsychology Assessment Metrics (ANAM)&#xD;
      consisting of:&#xD;
&#xD;
        -  Traditional Continuous Performance Test&#xD;
&#xD;
        -  Running Memory Continuous Performance Test&#xD;
&#xD;
        -  Simple Response Time&#xD;
&#xD;
        -  Procedural Response Time&#xD;
&#xD;
        -  Coding Substitution&#xD;
&#xD;
        -  Mathematics&#xD;
&#xD;
        -  Logical Relations&#xD;
&#xD;
        -  Matching-to-Sample&#xD;
&#xD;
        -  Stanford Sleepiness Scale&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale for Fatigue (VAS-F)</measure>
    <time_frame>at three months after initiating treatment with TYSABRI®</time_frame>
  </primary_outcome>
  <enrollment type="Actual">200</enrollment>
  <condition>Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        multicenter clinic patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of relapsing forms of MS.&#xD;
&#xD;
          2. Patients having an inadequate response to or unable to tolerate alternate MS&#xD;
             therapies.&#xD;
&#xD;
          3. Patient must be enrolled in the TOUCH prescribing program.&#xD;
&#xD;
          4. Recent MRI as part of the TOUCH prescribing program.&#xD;
&#xD;
          5. Patient must be between 18 and 55 years of age, inclusive.&#xD;
&#xD;
          6. EDSS between 0 and 5.5, inclusive.&#xD;
&#xD;
          7. Able to provide written informed consent.&#xD;
&#xD;
          8. Capable of completing the fatigue (MFIS, FSS, and VAS-F) and cognition (ANAM)&#xD;
             sessions.&#xD;
&#xD;
          9. A baseline VAS-F average score of &gt; 60.&#xD;
&#xD;
         10. Patient must be naÃƒ-ve to TYSABRI® treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients not enrolled in the TOUCH prescribing program.&#xD;
&#xD;
          2. History or presence of progressive multifocal leukoencephalopathy (PML).&#xD;
&#xD;
          3. Diagnosis of primary progressive MS (PPMS) or secondary progressive MS (SPMS) without&#xD;
             relapses.&#xD;
&#xD;
          4. Immunocompromised in the judgment of the investigator.&#xD;
&#xD;
          5. Allergy or hypersensitivity to TYSABRI®.&#xD;
&#xD;
          6. Prior history or current presence of a clinically significant medical illness or&#xD;
             laboratory abnormality, including any significant cardiac, endocrinologic,&#xD;
             hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal,&#xD;
             dermatologic, psychiatric, renal, and/or other major disease, that, in the opinion of&#xD;
             the investigator, would preclude the administration of TYSABRI®.&#xD;
&#xD;
          7. Women pregnant, breast feeding, or planning to become pregnant and women who are not&#xD;
             postmenopausal or surgically sterile, and unwilling to practice contraception.&#xD;
&#xD;
          8. A baseline average VAS-F score of &lt; 60.&#xD;
&#xD;
          9. Problems with upper extremity dexterity that could preclude usage of a computer mouse.&#xD;
&#xD;
         10. With educational completion below 8th grade school equivalent or non-fluent in&#xD;
             English.&#xD;
&#xD;
         11. Any other reason, in the opinion of both the Investigator and/or Sponsor, the patient&#xD;
             is determined not suitable for study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lake Barrington</city>
        <state>Illinois</state>
        <zip>60010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <zip>2421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003-3804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patchogue</city>
        <state>New York</state>
        <zip>11772</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6097</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guaynabo</city>
        <zip>00969</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2007</study_first_posted>
  <last_update_submitted>July 7, 2011</last_update_submitted>
  <last_update_submitted_qc>July 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Biogen Idec MD</name_title>
    <organization>Biogen Idec</organization>
  </responsible_party>
  <keyword>fatigue</keyword>
  <keyword>Tysabri</keyword>
  <keyword>cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

